Cargando…

Induction treatment in operable non-small cell lung cancer: the immune oncology era unfolds

Detalles Bibliográficos
Autor principal:	Walker, Paul R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407505/ https://www.ncbi.nlm.nih.gov/pubmed/37559643 http://dx.doi.org/10.21037/jtd-23-699

Ejemplares similares

Operable non-small cell lung cancer: induction therapy, adjuvant therapy, or both?
por: Agrafiotis, Apostolos C., et al.
Publicado: (2023)

The beginning of a new era in induction treatment for operable non-small cell lung cancer: a narrative review
por: Shinohara, Shuichi, et al.
Publicado: (2023)

Surgery for Non-Small Cell Lung Cancer in the Personalized Therapy Era
por: Chiappetta, Marco, et al.
Publicado: (2023)

Intraoperative molecular imaging in thoracic oncology: pushing the boundaries of precision resection for occult non-small cell lung cancer in the era of minimally invasive surgery
por: Azari, Feredun, et al.
Publicado: (2022)

Lung cancer treatment in the era of immunotherapy
por: Xu, Yang, et al.
Publicado: (2020)

Biobanking in the era of precision oncology
por: Saini, Kamal S., et al.
Publicado: (2015)

Biomarkers in the Era of Precision Oncology
por: Baxevanis, Constantin N.
Publicado: (2023)

Small Cell Lung Cancer: A New Era Is Beginning?
por: Morabito, Alessandro, et al.
Publicado: (2021)

Different Liquid Biopsies for the Management of Non-Small Cell Lung Cancer in the Mutational Oncology Era
por: Palmieri, Maria, et al.
Publicado: (2023)

Palliation in metastatic non-small cell lung cancer: Early integration with standard oncological care is the key
por: Singh, Navneet, et al.
Publicado: (2014)

Diagnosis and treatment of non-small cell lung cancer: current advances and challenges
por: Diebels, Ian, et al.
Publicado: (2022)

Could the clinical target volume be omitted for radiotherapy of locally advanced non-small cell lung cancer in the modern era?
por: Verma, Vivek, et al.
Publicado: (2021)

Individualized prognostic calculators in the precision oncology era
por: Taylor, Jeremy M.G., et al.
Publicado: (2019)

Dawn of a new era of diabeto‐oncology
por: Noto, Hiroshi
Publicado: (2020)

Radiation oncology in the new virtual and digital era
por: Aznar, Marianne C., et al.
Publicado: (2021)

TTF-1 and immune checkpoint therapy in non-small cell lung cancer
por: Gumbleton, Matthew, et al.
Publicado: (2023)

Controversies in oncology: surgery for small cell lung cancer? It’s time to rethink the case
por: Hoda, Mir Alireza, et al.
Publicado: (2018)

A new era of oncology through artificial intelligence
por: Curioni-Fontecedro, Alessandra
Publicado: (2017)

Systemic immune-inflammation index and prognosis of advanced non-small cell lung cancer
por: Alifano, Marco
Publicado: (2020)

Re-administration of immune checkpoint inhibitors for patients with non-small cell lung cancer
por: Hakozaki, Taiki
Publicado: (2022)

Immune checkpoint inhibitors for patients with gene-rearranged non-small cell lung cancer
por: Uehara, Yuji, et al.
Publicado: (2022)

Is smoking history the truly best biomarker for immune checkpoint inhibitor treatment in advanced non-small cell lung cancer?
por: Pirker, Robert
Publicado: (2018)

Histology Matters: Individualizing Treatment in Non-Small Cell Lung Cancer
por: Neal, Joel W.
Publicado: (2010)

Spotlight on the treatment of ALK-rearranged non-small-cell lung cancer
por: Mamdani, Hirva, et al.
Publicado: (2017)

Treatment strategy of EGFR-mutated non-small cell lung cancer
por: Tanaka, Fumihiro, et al.
Publicado: (2022)

Operating in an era of impact factor mania
por: Andersson, Arne, et al.
Publicado: (2015)

Curing Operable Stage I Non-Small Cell Lung Cancer With Stereotactic Ablative Body Radiotherapy: The Force Awakens
por: Siva, Shankar, et al.
Publicado: (2016)

Unfolding EHJ Open
por: Bäck, Magnus
Publicado: (2021)

Clinical impact of the systemic immune-inflammation index in non-small cell lung cancer patients
por: Shoji, Fumihiro
Publicado: (2020)

Treatments for Non-Small-Cell Lung Cancer: The Multiple Options for Precision Medicine
por: Pons-Tostivint, Elvire, et al.
Publicado: (2022)

Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer
por: Miura, Yosuke, et al.
Publicado: (2019)

Can postoperative complications be reduced by the application of ERAS protocols in operated non-small cell lung cancer patients?
por: Turna, Akif, et al.
Publicado: (2023)

Therapeutic revolution for inoperable stage III non-small cell lung cancer in the immune era
por: Li, Jiakang, et al.
Publicado: (2022)

Cryoablation and immunity in non-small cell lung cancer: a new era of cryo-immunotherapy
por: Velez, Antonio, et al.
Publicado: (2023)

Immune checkpoint inhibitors for non-small cell lung cancer patients on steroid or non-steroidal anti-inflammatory drugs treatment—therapeutic indication or therapeutic efficacy?
por: Kawase, Akikazu
Publicado: (2022)

The Lung Immune Prognostic Index (LIPI) stratifies prognostic groups in advanced non-small cell lung cancer (NSCLC) patients
por: Aldea, Mihaela, et al.
Publicado: (2020)

Palliative care in the era of novel oncological interventions: needs some “tweaking”
por: Power, Jenny, et al.
Publicado: (2022)

Advancements in next-generation sequencing for diagnosis and treatment of non-small-cell lung cancer
por: Lu, Ying-Qiang, et al.
Publicado: (2017)

Vistas in Non-Small Cell Lung Cancer (NSCLC) Treatment: of Kinome and Signaling Networks
por: Stravopodis, Dimitrios J., et al.
Publicado: (2023)

Sublobar Resection for Early-Stage Lung Cancer: An Oncologically Valid Procedure?
por: Diebels, Ian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dvjc423g9nt4m54bjtb4t4rfsh